Folate News and Research

RSS

HealthCore study shows Metanx tablets reduces health plan costs

Diabetic patients diagnosed with peripheral neuropathy had lower medical costs and reduced use of anticonvulsant medications when treated with a folate-enriched prescription medical food, according to data presented today at the International Society for Pharmacoeconomics and Outcomes Research 12th Annual European Congress.

27 Oct 2009

£17,000 grant to university researcher for breast cancer research

A researcher at the University of Sheffield is set to investigate whether women with a mutation in a gene that prevents folate (vitamin B9) working effectively may be at increased risk of breast cancer.

21 Oct 2009

Blocking folic acid action during early pregnancy leads to increased risk of abnormalities in growing baby

Using medication that reduces or blocks the actions of folic acid during the first trimester of pregnancy (weeks 1-12), increases the risk that the growing baby will develop abnormalities. This conclusion was reached by a team of Epidemiologists, Paediatricians, Clinical Pharmacologists, Obstetricians and Gynaecologists who examined birth and abortion data collected in Israel between 1998 and 2007.

15 Oct 2009

Medications to reduce folic acid during pregnancy increase the risk of abnormalities in fetus

Pregnant women are advised to take vitamin supplements containing folic acid as part of their routine pre-natal care. Now, a new study warns that taking medications that reduce or block the actions of folic acid during the first trimester of pregnancy increase the risk that the growing baby will develop abnormalities.

14 Oct 2009

Inflammation markers not involved with the chemopreventative effect of aspirin on colorectal adenomas

Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute.

13 Oct 2009

Michelle’s Miracle raises $750,000 in its first tranche of Series A funding

Michelle’s Miracle, Inc the leading provider of tart cherry nutraceutical products announced that it has closed its first tranche of Series A funding after raising approximately $750,000 in equity.

30 Sep 2009

Morphotek announces preliminary data from Phase II trial of farletuzumab

Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).

26 Sep 2009

Folotyn approved for the treatment of Peripheral T-Cell Lymphoma

The U.S. Food and Drug Administration has approved Folotyn (pralatrexate), the first treatment for a form of cancer known as Peripheral T-cell Lymphoma (PTCL), an often aggressive type of non-Hodgkins lymphoma.

25 Sep 2009

Components of insulin-control system can reset body's biological clock

Many of the genes that regulate insulin also alter the timing of the circadian clock, a new study has found.

18 Sep 2009

Insulin metabolism regulates body's internal clock

While scientists have known for several years that our body's internal clock helps regulate many biological processes, researchers have found that the reverse is also true: Many common biological processes - including insulin metabolism - regulate the clock, according to a new study by investigators at the University of Pennsylvania School of Medicine, the Genomics Institute of the Novartis Research Foundation, and the University of California at San Diego.

18 Sep 2009

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

3 Sep 2009

Endocyte receives payment for the advancement of epothilone-folate anti-cancer agent

Endocyte, Inc., a cancer drug discovery and development company, today announced it has received a milestone payment from Bristol-Myers Squibb Company (NYSE: BMY). This payment was triggered by the commencement of a Phase II clinical trial for an epothilone-folate anti-cancer agent identified through the collaboration between Endocyte and Bristol-Myers Squibb scientists.

26 Aug 2009

Endocyte announces results from study of EC145 in patients with advanced non-small cell lung cancer

Results were presented at the 13th World Conference on Lung Cancer in San Francisco. The single arm Phase II study evaluated the therapeutic agent EC145 and the molecular imaging agent EC20 in 42 patients with advanced adenocarcinoma of the lung. Forty percent of patients involved in the clinical trial had already failed at least four chemotherapy regimens prior to enrollment in the study.

12 Aug 2009

Reversible cell-specific drug delivery with aptamer-functionalized liposomes

For cancer drug developers, finding an agent that kills tumor cells is only part of the equation. The drug must also spare healthy cells, and - ideally - its effects will be reversible, to cut short any potentially dangerous side effects.

6 Aug 2009

Targeted nanoparticles boost arsenic’s anticancer punch

Arsenic trioxide has a long history as a potent human poison, but it also has proven valuable as one of the primary treatment options for acute promyelocytic leukemia. Efforts to use arsenic trioxide to treat other types of cancer are under way, but clinical trials are revealing that the extreme toxicity of this material is likely to limit its utility as a broad-spectrum anticancer agent.

21 Jul 2009

A new prostate cancer "homing device" for drug delivery

A new prostate cancer "homing device" could improve detection and allow for the first targeted treatment of the disease. A team of Purdue University researchers has synthesized a molecule that finds and penetrates prostate cancer cells and has created imaging agents and therapeutic drugs that can link to the molecule and be carried with it as cargo.

6 Jul 2009